• Geron will discontinue its Phase 3 IMpactMF trial of imetelstat in patients with myelofibrosis relapsed or refractory to JAK inhibitors.
• An independent monitoring committee concluded the trial was unlikely to meet its primary goal of improving overall survival.
• No new safety signals changed imetelstat’s known safety profile or required additional monitoring.
• Detailed data analysis is planned, with study findings to be presented to the scientific community at a future date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854656) on October 28, 2026, and is solely responsible for the information contained therein.